Karyopharm Therapeutics (KTarget PriceI) Getting Somewhat Negative News Coverage, Study Finds

Karyopharm Therapeutics (KTarget PriceI) Getting Somewhat Negative News Coverage, Study Finds

News articles about Karyopharm Therapeutics (NASDAQ:KPTI) have been trending somewhat negative this week, according to Alpha One Sentiment. Alpha One, a division of Accern, identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Karyopharm Therapeutics earned a daily sentiment score of -0.08 on Alpha One’s scale. Alpha One also assigned news articles about the company an impact score of 86 out of 100, meaning that recent media coverage is very likely to have an effect on the company’s share price in the near future.

Here are some of the news articles that may have effected Alpha One’s rankings:

Karyopharm Therapeutics (NASDAQ:KPTI) traded up 0.57% on Friday, hitting $8.88. The company’s stock had a trading volume of 237,099 shares. Karyopharm Therapeutics has a 12 month low of $6.27 and a 12 month high of $14.63. The firm’s market cap is $418.41 million. The firm has a 50 day moving average of $9.76 and a 200 day moving average of $10.23.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.04. The company had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.02 million. During the same period in the prior year, the firm earned ($0.75) earnings per share. Equities research analysts forecast that Karyopharm Therapeutics will post ($2.68) earnings per share for the current fiscal year.

A number of research analysts have commented on the company. ValuEngine lowered Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price target on shares of Karyopharm Therapeutics in a research report on Monday, May 15th. Jefferies Group LLC reaffirmed a “buy” rating and set a $17.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, April 7th. Robert W. Baird reaffirmed an “outperform” rating and set a $15.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday, April 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, April 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $14.46.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:KPTI”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment